作者: Eleftherios Pelechas , Alexandra Papoudou-Bai , Paraskevi V Voulgari , Alexandros A Drosos , None
DOI: 10.1007/S00296-018-4212-0
关键词: Prednisone 、 Medicine 、 Dermatology 、 Rheumatoid arthritis 、 Tocilizumab 、 Hydroxychloroquine 、 Skin biopsy 、 Granuloma annulare 、 Rheumatology 、 Infliximab 、 Internal medicine
摘要: Granuloma annulare (GA) is the most common non-infectious disease. Despite fact that it a benign disease, can be associated with variety of disorders and certain drugs including biological disease-modifying anti-rheumatic (bDMARDs). A 50-year-old man history rheumatoid arthritis refractory to methotrexate, hydroxychloroquine infliximab was treated tocilizumab (TCZ), an interleukin-6 receptor antagonist, 162 mg subcutaneously every week. The patient responded very well TCZ treatment decrease acute phase reactants reduction disease activity score for 28-joints count. However, 3 months later he developed erythematous polycyclic eruptions affecting lower extremities consistent diagnosis GA which confirmed by skin biopsy. has been discontinued prednisone presenting complete resolution manifestations after 4 weeks. This first case development during treatment. Thus, we review literature discuss relevant cases in patients bDMARDs. When dealing these agents, all physicians should aware possible adverse events potential such complications.